Biolipox AB
Executive Summary
Founded in June 2000 by two professors from Sweden's Karolinska Institute, Biolipox AB is focusing on the role of arachidonic acid in inflammation, and looking to develop an improved family of respiratory and anti-inflammatory drugs.
You may also be interested in...
NicOx/AstraZeneca: Transparency vs. Partnering
AstraZeneca's news that nitric oxide donator AZD 3582 had failed to reach a primary end-point in a Phase II trial sent originator NicOx's shares plummeting, as investors lost faith in the biotech's entire platform. NicOx is disputing the data's accuracy in an attempt to salvage investor confidence--and to survive. The events highlight the tension between Big Pharma's duties to investor transparency and to protect its biotech partners. They're also a reminder to biotechs that there's more to deals than just royalties.
NicOx: Challenging the Cox-2s?
Recent concerns over the cardiovascular risk profile of Cox-2 inhibitors strengthen the case for pain compound AZD 3582, a new formulation of naproxen in Phase II trials at AstraZeneca. For the compound's originator, NicOx, forthcoming trial results will be critical in validating the firm's founding concept: grafting a nitric oxide molecule onto existing generic drugs.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.